These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1961279)

  • 1. Patent protection upheld in Amgen/Genetics Institute battle over EPO.
    Riley J; Pristave R
    Nephrol News Issues; 1991 Apr; 5(4):18-9. PubMed ID: 1961279
    [No Abstract]   [Full Text] [Related]  

  • 2. Amgen protects its billion dollar protein.
    Chahine K
    Nat Biotechnol; 1997 Jun; 15(6):496-7. PubMed ID: 9181560
    [No Abstract]   [Full Text] [Related]  

  • 3. Amgen preserves erythropoietin monopoly for now.
    Chahine K
    Nat Biotechnol; 2001 Mar; 19(3):188. PubMed ID: 11231519
    [No Abstract]   [Full Text] [Related]  

  • 4. Promega changes tack in battle over patent.
    Knight J
    Nature; 2003 Nov; 426(6965):373. PubMed ID: 14647346
    [No Abstract]   [Full Text] [Related]  

  • 5. First round to Amgen in EPO battle.
    Robertson D
    Nat Biotechnol; 2000 May; 18(5):483. PubMed ID: 10802602
    [No Abstract]   [Full Text] [Related]  

  • 6. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotechnology patent disputes. Amgen plays for time.
    Gershon D
    Nature; 1990 Apr; 344(6269):800. PubMed ID: 2330034
    [No Abstract]   [Full Text] [Related]  

  • 8. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2008 Nov; 7(11):882-3. PubMed ID: 18974746
    [No Abstract]   [Full Text] [Related]  

  • 9. Patent. Battle lines are drawn over generic AIDS drug.
    AIDS Policy Law; 2005 Aug; 20(16):6. PubMed ID: 16161208
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug patent protection: how long is long enough?
    Sibbald B
    CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
    [No Abstract]   [Full Text] [Related]  

  • 11. International patent protection for HIV-related therapies: patent attorney's perspective.
    Pavento LC; Greene JL; McDonald JK
    Emory Int Law Rev; 2003; 17(2):919-31. PubMed ID: 15199935
    [No Abstract]   [Full Text] [Related]  

  • 12. Proposed changes to patent code loom over biotech industry.
    Coombs A
    Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010
    [No Abstract]   [Full Text] [Related]  

  • 13. EPO patient dispute: court battle ends at the start.
    Gershon D
    Nature; 1989 Dec 21-28; 342(6252):846. PubMed ID: 2594071
    [No Abstract]   [Full Text] [Related]  

  • 14. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract]   [Full Text] [Related]  

  • 15. Patent watch: EPO rejects reach through claims.
    Nat Rev Drug Discov; 2010 Jan; 9(1):12. PubMed ID: 20043023
    [No Abstract]   [Full Text] [Related]  

  • 16. Roche faces charges over Taq patent claim.
    Abbott A
    Nature; 1996 Aug; 382(6593):660. PubMed ID: 8751427
    [No Abstract]   [Full Text] [Related]  

  • 17. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
    AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916
    [No Abstract]   [Full Text] [Related]  

  • 18. Cabilly patent finale.
    Waltz E
    Nat Biotechnol; 2008 Aug; 26(8):846. PubMed ID: 18688222
    [No Abstract]   [Full Text] [Related]  

  • 19. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

  • 20. Patent watch: Progress in three key patent disputes in 2009.
    Nat Rev Drug Discov; 2010 Jan; 9(1):12-3. PubMed ID: 20050395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.